Blank Cover Image

Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism

フォーマット:
論文
責任表示:
Karashima, Shigehiro ; Yoneda, Takashi ; Kometani, Mitsuhiro ; Ohe, Masashi ; Mori, Shunsuke ; Sawamura, Toshitaka ; Furukawa, Kenji ; Seta, Takashi ; Yamagishi, Masakazu ; Takeda, Yoshiyu
言語:
英語
出版情報:
日本高血圧学会 = Japanese Society of Hypertension, 2016-03-01
著者名:
Karashima, Shigehiro
Yoneda, Takashi
Kometani, Mitsuhiro
Ohe, Masashi
Mori, Shunsuke
Sawamura, Toshitaka
Furukawa, Kenji
Seta, Takashi
Yamagishi, Masakazu
Takeda, Yoshiyu
続きを見る
掲載情報:
Hypertension Research
ISSN:
0916-9636  CiNii Articles  Webcat Plus  JAIRO
巻:
39
通号:
3
開始ページ:
133
終了ページ:
137
バージョン:
author
概要:
The mineralocorticoid receptor (MR) is expressed in the kidneys and in adipose tissue, and primary aldosteronism (PA) is associated with metabolic syndrome. This study assessed the effects of MR blockade by eplerenone (EPL) and spironolactone (SPL) on blood pressure (BP) and metabolic factors in patients with PA. Fifty-four patients with PA were treated with one of two MRAs, EPL (25-100 mg daily, n=27) or SPL (12.5-100 mg daily, n=27) for 12 months. Visceral (VAT) and subcutaneous adipose tissue were quantified using CT and FatScan imaging analysis software. Body mass index, homeostasis model assessment-insulin resistance (HOMA-IR), serum creatinine, potassium and lipids, urinary albumin excretion (UAE) and plasma aldosterone concentration (PAC) and plasma renin activity (PRA) were measured before and after treatment. EPL and SPL decreased BP and increased serum potassium levels to similar degrees. PAC and PRA did not differ between the two groups. Although treatment with the MRAs did not change HOMA-IR or serum lipids, they significantly decreased UAE and VAT (P<0.05). These results suggest that EPL and SPL are effective and safe for the treatment of PA. The long-term metabolic and renal effects of these MRAs should be further investigated. © 2016 The Japanese Society of Hypertension. All rights reserved.<br />Embargo Period 6 months 続きを見る
URL:
http://hdl.handle.net/2297/44875
タイトル・著者・出版者が同じ資料

類似資料:

1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
11
 
12
 

Kometani, Mitsuhiro, Yoneda, Takashi, Demura, Masashi, Karashima, Shigehiro, Mori, Shunsuke, Oe, Masashi, Sawamura, &hellip;

Japanese Society of Internal Medicine = 日本内科学会

Demura, Masashi, Demura, Yoshiki, Ameshima, Shingo, Ishizaki, Takeshi, Sasaki, Masato, Miyamori, Isamu, Yamagishi, &hellip;

Elsevier

Demura, Masashi, Wang, Fen, Yoneda, Takashi, Karashima, Shigehiro, Mori, Shunsuke, Oe, Masashi, Kometani, Mitsuhiro, &hellip;

Wolters Kluwer Health / Lippincott Williams & Wilkins

Wakabayashi, Yusuke, Oka, Rie, Nakaya, Masako, Karashima, Shigehiro, Kometani, Mitsuhiro, Sakurai, Masaru, Yoshimura, &hellip;

Hindawi Publishing Corporation

Demura, Masashi, Yoneda, Takashi, Karashima, Shigehiro, Higashikata, Toshinori, Mabuchi, Hiroshi, Kawano, Mitsuhiro, &hellip;

BioMed Central

Okada, Toshihide, Mibayashi, Hiroshi, Hasatani, Kenkei, Hayashi, Yoshiaki, Tsuji, Shigetsugu, Kaneko, Yoshibumi, &hellip;

Baishideng Publishing Group

Kometani, Mitsuhiro, Yoneda, Takashi, Demura, Masashi, Koide, Hiroshi, Nishimoto, Koshiro, Mukai, Kuniaki, &hellip;

Nature Publishing Group

Yamaaki, Naoto, Yagi, Kunimasa, Kobayashi, Junji, Nohara, Atsushi, Ito, Naoko, Asano, Akimichi, Nakano, Kaoru, Liu, &hellip;

Hindawi Publishing Corporation

Aono, Daisuke, Oka, Rie, Kometani, Mitsuhiro, Takeda, Yoshimichi, Karashima, Shigehiro, Yoshimura, Kenichi, Takeda, &hellip;

Hindawi Publishing Corporation

Oka, Rie, Shibata, Kyoko, Sakurai, Masaru, Kometani, Mitsuhiro, Yamagishi, Masakazu, Yoshimura, Kenichi, Yoneda, &hellip;

Hindawi Limited

蘇馬, 由衣, 大家, 理恵, 藤井, 寿美枝, 伊藤, 直子, 米谷, 充弘, 唐島, 成宙, 武田, 仁勇, &hellip;

日本老年医学会 = The Japan Geriatrics Society

Okazaki-Sakai, Satoko, Yoshimoto, Sachiko, Yagi, Kunimasa, Wakasugi, Takanobu, Takeda, Yoshiyu, Yamagishi, Masakazu

Japanese Society of Internal Medicine = 日本内科学会